Firm
EA, owner of video games including Madden and The Sims, will be sold to a consortium including Saudi Arabia’s Public Investment Fund and a firm owned by Donald Trump’s son-in-law
Eszter Szakács, partner at Danubia in Hungary, discusses women’s progression, workplace flexibility, and how to deal with imposter syndrome
In the second instalment of our data-led special reports, Managing IP speaks to the most prolific representatives for REUDs on how they manage their team and filing strategies
A Full Federal Court ruling on the patent-eligibility of computer-implemented inventions in Australia could pave the way for more filings
Sponsored
Sponsored
-
Sponsored by Anand and AnandAchuthan Sreekumar of Anand and Anand draws on a recent High Court of Delhi ruling on the unauthorised use of Ratan Tata’s identity to consider how Indian jurisprudence protects well-known personal names -
Sponsored by Tahota Law FirmCharles Feng, Lian Xue, and Chenxi Cui of Tahota Law Firm draw on the case and several other legal disputes to explore the fractious relationship between games console emulators and manufacturers
-
Sponsored by Liu, Shen & AssociatesJun Qiu of Liu, Shen & Associates analyses two recent CNIPA decisions that provide insights into the application of the good faith principle in patent re-examination and invalidation procedures in China
-
Sponsored by TOPPAN Digital IPThe team at TOPPAN Digital IP believe there are key flaws in current intellectual property systems and services. Managing IP hears how the company’s STREAM IP platform is aimed at addressing them
-
Sponsored by Liu, Shen & AssociatesDongguo Liang of Liu, Shen & Associates says DeepSeek should take swift action to address ‘insufficient planning’ in its intellectual property protection strategy and an ‘underdeveloped’ patent portfolio
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property considers the CNIPA’s evidentiary standards after its invalidation of a patent for the crystalline form of lemborexant and explains the implications for pharmaceutical patent strategies in China
